The use of surrogate endpoints in regulating medicines for cardio-renal disease: opinions of stakeholders.
There is discussion whether medicines can be authorized on the market based on evidence from surrogate endpoints. We assessed opinions of different stakeholders on this topic.We conducted an online questionnaire that targeted various stakeholder groups (regulatory agencies, pharmaceutical industry,...
Main Authors: | Bauke Schievink, Hiddo Lambers Heerspink, Hubert Leufkens, Dick De Zeeuw, Jarno Hoekman |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4182561?pdf=render |
Similar Items
-
The geographical distribution of leadership in globalized clinical trials.
by: Jarno Hoekman, et al.
Published: (2012-01-01) -
Surrogate Endpoints in Medicine
by: Sudhir Srivastava, et al.
Published: (2002-01-01) -
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)
by: Hans-Henrik Parving, et al.
Published: (2012-09-01) -
Statistical Analysis in Surrogate Endpoints
by: SU, TE-CHIH, et al.
Published: (1998) -
How to measure and monitor albuminuria in healthy toddlers?
by: Sophie Marielle van den Belt, et al.
Published: (2018-01-01)